Anbio Biotechnology Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $8.6M+5.6% YoYTTM through 31 Dec 2025
Net Income $6.4M+169.9% YoYTTM through 31 Dec 2025
Free Cash Flow -$6.7MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 87.2% |
| Operating Margin | 66.7% |
| Net Margin | 74.1% |
Returns
27.1%ROE
21.2%ROA
15.2%ROIC
Balance Sheet Health
Debt / Equity0.00x
Current Ratio336.00x
Net Debt-$11.9Mnet cash position
Cash & Equivalents$7.8M
Quality Metrics
Altman Z-Score1,676.18
Piotroski F-Score4 / 9
FCF Margin-77.9%
Multi-Year Trend
RevenueFY2025: $8.6M
Diluted EPS$0.15TTMFY2025: $0.15
Dividend
No dividend
Capital Allocation
R&D Spend$201.3K
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Non-COVID-19 related products | $7M | View detailsThe primary growth driver as the company successfully diversifies away from pandemic-related products. | |
| Respiratory diseases and COVID-19 related products | $1.7M | View detailsDeclined significantly from 54% of revenue in FY2024 and 60% in FY2023 as pandemic-related demand normalized. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.